This is a YMYL article on a fast-evolving clinical topic \u2014 anaesthesia guidance on GLP-1 medications has been updated several times since 2023. Your surgeon, anaesthesiologist and the doctor who prescribes your Ozempic are the authoritative sources for your specific case. The guidance below reflects current consensus from the American Society of Anesthesiologists (ASA)<\/a>, the Association of Anaesthetists of Great Britain and Ireland (AAGBI), and major surgical societies \u2014 but it is general patient information, not personal medical advice.<\/p>\n\n\n\n For facelift surgery under general anaesthesia, Ozempic should be stopped at least 1 week (one missed weekly dose) before surgery<\/strong> per ASA 2023 guidance \u2014 many surgeons request 2 weeks, particularly at higher semaglutide doses. The clinical reason is anaesthesia safety: Ozempic significantly slows gastric emptying, raising the risk of residual stomach content during anaesthetic induction and possible aspiration into the lungs. Beyond the anaesthesia stop, weight should be stable for 2\u20133 months before facelift surgery \u2014 patients still losing weight at the time of surgery can develop new facial laxity after the lift settles. Many Ozempic patients also discuss fat transfer at the same time as facelift to restore lost facial volume. Ozempic can usually be resumed 2\u20134 weeks post-op once normal eating is established. Your surgeon and the doctor who prescribed your Ozempic must agree the timing.<\/p>\n\n\n\n Ozempic is the brand name (developed by Novo Nordisk) for semaglutide<\/strong>, a once-weekly injectable GLP-1 receptor agonist. It was first approved for type 2 diabetes, and the same molecule under the brand name Wegovy<\/strong> is approved for weight management. In many countries Ozempic itself is prescribed off-label or privately for weight loss. There is also an oral form of semaglutide called Rybelsus<\/strong>, taken daily.<\/p>\n\n\n\n Clinical effects: semaglutide reduces appetite, increases satiety, and significantly slows gastric emptying. Clinical trials at full weight-loss doses have shown average weight loss in the range of 10\u201315% of body weight over a year. It is one of the most widely prescribed weight-loss medications globally, and a significant portion of cosmetic surgery patients in 2026 are on it or have recently used it.<\/p>\n\n\n\n Related medications in the same family include tirzepatide<\/strong> (Mounjaro \/ Zepbound), liraglutide<\/strong> (Saxenda \u2014 daily injection), and others. The pre-op principles in this guide apply to all of them, with some differences in timing covered below. See our companion article on Mounjaro before tummy tuck<\/a> for the tirzepatide-specific guidance, which uses the same framework.<\/p>\n\n\n\n “Ozempic face” isn’t a clinical diagnosis \u2014 it’s a popular term for the facial appearance changes that can follow significant rapid weight loss on any GLP-1 medication. The face has several deep fat compartments (cheek, temple, peri-orbital, peri-oral). When body weight reduces substantially over months, these compartments deflate. The result: hollowed temples, flatter cheeks, deeper nasolabial folds, and a more aged appearance \u2014 sometimes called “deflated” by patients.<\/p>\n\n\n\n Several real factors contribute:<\/p>\n\n\n\n Many patients arriving for facelift consultations in 2026 specifically cite Ozempic face as the prompt. The good news: facelift addresses the skin laxity component very effectively. The volume component is best addressed by combining facelift with fat transfer (or sometimes filler), which is increasingly common \u2014 discussed below.<\/p>\n\n\n\n The reason to stop Ozempic before surgery isn’t the weight loss \u2014 it’s the gastric effect.<\/strong> Semaglutide significantly slows gastric emptying. Food and fluid can remain in the stomach much longer than normal after meals. During the induction of general anaesthesia, residual stomach content can be regurgitated and inhaled into the lungs \u2014 known as aspiration \u2014 which can cause aspiration pneumonia or, rarely, more serious airway complications. Standard pre-op fasting protocols were designed assuming normal gastric emptying. On Ozempic, that assumption no longer holds. The cessation period allows the stomach to return to normal emptying before surgery.<\/p>\n\n\n\n Several anaesthesia case reports between 2022 and 2024 documented residual gastric content in patients on GLP-1 medications who had followed standard fasting. These reports prompted updated guidance from anaesthesia societies. The risk is procedure-independent \u2014 it applies to any surgery under general anaesthesia or deep sedation, including facelift.<\/p>\n\n\n\n Current consensus guidance:<\/p>\n\n\n\n Your anaesthesiologist makes the final call. Do not stop or change your Ozempic dose without consulting both your prescribing doctor and the surgical team.<\/strong><\/p>\n\n\n\n Beyond anaesthesia safety, there’s a result-quality reason to be at a stable weight before facelift. Facelift addresses skin laxity that already exists \u2014 it tightens what is there. If your body is still actively losing weight at the time of surgery, several things can happen:<\/p>\n\n\n\n The clinical ideal: reach your target weight, hold it for 2\u20133 months to confirm stability, and then have facelift surgery on a stable facial structure. Most surgeons require this stable period before booking.<\/p>\n\n\n\n For Ozempic patients whose main concern is facial volume loss as well as skin laxity, facelift alone may not be the full answer. The skin will be tightened \u2014 but the underlying volume deficit remains. Many surgeons therefore now combine facelift with one of:<\/p>\n\n\n\n For Ozempic patients with significant volume loss, this combination approach often produces a more natural-looking, refreshed result than facelift alone. Discuss with your surgeon during consultation \u2014 they’ll assess which combination suits your specific volume deficit and skin laxity.<\/p>\n\n\n\n Active weight loss on Ozempic under prescriber supervision. Reach a healthy stable weight.<\/p>\n\n\n\n Maintain target weight for at least 8\u201312 weeks. Ozempic may continue at maintenance dose during this period. Facial volume changes should have stabilised. Surgical team confirms readiness.<\/p>\n\n\n\n Standard pre-op work-up (bloods, ECG, anaesthesia review). Stop smoking if you haven’t already \u2014 facelift requires 4\u20136 weeks of cessation. Medical clearance<\/a> finalised.<\/p>\n\n\n\n Last Ozempic dose at least 1 week before surgery (some surgeons request 2 weeks). Confirmed in writing with both your prescribing doctor and the surgical anaesthesia team.<\/p>\n\n\n\n Facelift (possibly combined with fat transfer). Follow standard pre-op fasting plus any extended fasting protocol the anaesthesia team requests. Disclose all medications honestly during pre-op check-in.<\/p>\n\n\n\n Soft diet, gradual normal eating, healing protein priority. Ozempic typically held while you’re transitioning back to normal eating.<\/p>\n\n\n\n Once eating normally and healing is on track, Ozempic can usually be resumed at maintenance dose. Some patients restart at a lower dose to re-acclimatise.<\/p>\n\n\n\n For procedure-specific facelift recovery detail, see our facelift recovery day-by-day guide<\/a>.<\/p>\n\n\n\n Resuming too early can cause nausea (uncomfortable with facial surgery and increases blood pressure during the bruising phase) and may reduce protein\/calorie intake needed for wound healing. Resuming too late may allow some weight rebound. Typical guidance:<\/p>\n\n\n\n Many facelift patients resume Ozempic between week 2 and week 4 post-op. Some patients who reached goal weight choose to discontinue Ozempic at this point (with prescriber guidance) and rely on lifestyle. Others continue at maintenance dose long-term.<\/p>\n\n\n\n Yes \u2014 all these are GLP-1 medications (Mounjaro is dual GIP\/GLP-1) that slow gastric emptying. Pre-op timing:<\/p>\n\n\n\nTable of contents<\/h3>\n\n\n\n
\n
The short answer<\/h2>\n\n\n\n
What is Ozempic (semaglutide)?<\/h2>\n\n\n\n
The “Ozempic face” phenomenon<\/h2>\n\n\n\n
\n
The clinical issue: delayed gastric emptying<\/h2>\n\n\n\n
How long to stop Ozempic before facelift<\/h2>\n\n\n\n
\n
![\"Ozempic](\"https:\/\/revitalizeinturkey.com\/wp-content\/uploads\/2026\/05\/ozempic-before-facelift-infographic-519x1024.jpg\" "\\"\\"")
Why weight stability matters before facelift<\/h2>\n\n\n\n
\n
Fat transfer with facelift \u2014 the volume question<\/h2>\n\n\n\n
\n
The combined pre-op timeline<\/h2>\n\n\n\n
Months -12 to -3: Weight optimisation<\/h3>\n\n\n\n
Months -3 to -1: Weight stability<\/h3>\n\n\n\n
Weeks -2 to -1: Pre-op preparation<\/h3>\n\n\n\n
Week -1 (or earlier): Stop Ozempic<\/h3>\n\n\n\n
Day 0: Surgery<\/h3>\n\n\n\n
Weeks 1\u20132 post-op: No Ozempic yet<\/h3>\n\n\n\n
Weeks 2\u20134 post-op: Resume Ozempic per medical advice<\/h3>\n\n\n\n
When to resume Ozempic after facelift<\/h2>\n\n\n\n
\n
Wegovy, Mounjaro, Saxenda \u2014 same principles?<\/h2>\n\n\n\n